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ABSTRACT 
 
Miniard, Brock Michael. M.S., Department of Biological Sciences, Wright State 
University, 2012. 
Expression of Inflammatory Response Genes in Ferrets Challenged with H5N1 Avian 
Influenza Virus 
 
 
 
 
Influenza A H5N1 has emerged as a potential to be the next pandemic influenza.  Ferrets 
are a promising model of H5N1 infection because the disease progression is similar to 
that known in humans, however reagents to characterize infections in ferrets are few.  We 
developed real-time PCR assays for the ferret cytokines IL-1β, IL-2, IL-4, IL-8, IL-
12p40, TNF-α, IFN-α, IFN-β, IFN-γ, TGFB-β1, and TGFB-β2.  Forty-eight ferrets were 
vaccinated with either one of three vaccine formulations (Vaccine 1, Vaccine 2, or 
Vaccine 3), or saline (0.9% NaCl), then challenged intranasally with a lethal dose of 
H5N1 strain A/Vietnam/1203/04.  Cytokine assays were then performed on blood drawn 
pre-vaccination, 0, 3, 4, and 14 days post infection, and brain, lung, and liver samples 
from ferrets euthanized either 4 or 14 days post infection or when found moribund.  
Ferrets vaccinated with Vaccine 1 showed an increase in IL-2, IL-6, IL-12p40, and IFN-
β, and a decrease in TNF-α in the blood, an increase in IL-1β and TNF-α in the brain, an 
increase of IFN-β and IFN-γ in the lung, and an increase of IFN-γ in the liver during the 
course of infection.  Ferrets vaccinated with Vaccine 2 showed an increase in IL-2, IL-
12p40, IFN-α, IFN-β, IFN-γ, and TGFB-β2, and a decrease in TNF-α in the blood, an 
increase of IL-1β in the brain, an increase of IFN-β and IFN-γ in the lung, and little 
 
iv 
variance of cytokine levels in the liver during the course of infection.  Ferrets vaccinated 
with Vaccine 3 showed a decrease in IL-2, IL-6, IL-8, IL-12p40, and TNF-α in the blood, 
little variance of cytokine levels in the brain and liver, and an increase in IL-4 in the lung 
during the course of infection.  Ferrets with the saline control showed an increase in IL-2, 
and a decrease in IL-12p40, TNF-α and IFN-β in the blood, an increase of IL-1β, IL-8 
and TNF-α in the brain, an increase of IFN-β and IFN-γ in the lung, and an increase of 
TNF-α and IFN-γ in the liver during the course of infection.  Vaccine 3 conferred total 
protection, as indicated by 100% survival of the ferrets in that group.  Vaccines 1 and 2 
conferred some protection, with 22% and 33% of ferrets, respectively surviving.  This 
study exhibits a promising vaccine in Vaccine 3 as well a new reagents for characterizing 
ferret immune responses, which may be useful in evaluating potential vaccine or 
therapeutic efficacy. 
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Introduction 
Influenza 
Influenza is an upper respiratory tract infection caused by the influenza virus 
(WHO 2009).  The disease is characterized by high fever, myalgia, headache and severe 
malaise, non-productive cough, sore throat, and rhinitis.  The virus is endemic, with 
seasonal outbreaks which affect 5-15 percent of the world population, with three to five 
million cases per year and  250,000 to 500,000 deaths, especially in the elderly and 
chronically ill. 
The virus is a member of the Orthomyxoviridae family of viruse, with this family 
divided into three genera: influenza A, influenza B, and influenza C (Maines 2008).  
Influenza A and B typically cause seasonal epidemics (WHO 2009, CDC 2009) but 
influenza C can also cause disease in humans.  Influenza A, B, and C are classified based 
on the antigenic properties of matrix proteins or nucleoproteins (Zaraket 2009).  
Influenza A viruses are typed based on two surface glycoproteins, hemagglutinin (HA), 
and neuraminidase (NA)
  
(Maines 2008), and named based on which HA and NA the 
virus carries.  For example, the current influenza A strains circulating among humans are 
H1N1 and H3N2 (CDC 2009).  Influenza A has 15 sero-types of HA and 9 known sero-
types of NA, while influenza B has only one sero-type of HA and NA (Maines 2008).  
Influenza C expresses a hemagglutinin-esterase (HE) instead of HA, but HE is 
homologous to HA in function (Zaraket 2009).  Influenza virus infects host-cells by 
binding to sialic acid galactose on the cell surface via HA on the virion.   NA cleaves 
sialic acid to release the virion from the cell (Maines 2008).  Antigenic drift causes 
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frequent changes to the HA and NA proteins, which is due to the low proof reading 
capability of the RNA polymerase and to selective pressures exerted on the proteins by 
the host immune system. 
Influenza has a segmented genome which allows antigenic shift that gives rise to 
reassortment of virion genes in the host when two antigenically different viruses co-infect 
the host (Maines 2008, Zaraket 2009).  Influenza is an enveloped virus with ten gene 
products grouped into eight negative-sense RNA segments.  Two of them are the HA and 
NA described above.  Three polymerase proteins (PB1, PB2, and PA) form a RNA-
dependent RNA polymerase.  Nucleoprotein (NP) is involved in formation of the viral 
capsid, and along with the polymerase proteins, compose the ribonuclearprotein complex.  
The M segment contains two genes which encode for the matrix protein 1 (M1) and 
matrix protein 2 (M2).  M1 forms a protein layer between the nucleocapsid and the 
envelope.  M2 is found in the viron envelope which is obtained from budding through the 
cell membrane, and acts as an ion channel to acidify the virion during viral uncoating, 
which releases the nucleocapsid into the cell.  The nonstructural proteins (NS1 and NS2) 
are involved in neutralization of host antiviral responses and nuclear export of viral 
ribonuclear proteins. 
Influenza A, B, and C appear to have a common ancestor, with influenza C 
branching off first, followed by branching of influenza A and B (Maines 2008).  A and B 
show more homology between genes than either does with influenza C, with the 
polymerase genes showing the highest homology in A and B of 60%.  Influenza A shows 
the most antigenic diversity, with its many HA and NA types, while influenza B and C 
exhibit a more conserved and more slowly evolving genetic phylogeny.  
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The natural hosts of influenza A viruses are considered to be birds, with 
waterfowl being the most common carriers (Zaraket 2009).  All HA and NA types of 
influenza A are found in avian hosts, while only a handful of types have been observed in 
humans (HA types H1, H2, H3, H5, H7, and H9, and NA types N1, N2, and N3).  A 
viral-host equilibrium is expected to form between a host and infecting virus, resulting in 
little to no damage in the host but with a high proportion of the host population infected 
and efficient replication occurring in the host.  Influenza A is ubiquitous in avian hosts 
and is usually asymptomatic in birds.  This suggests a possible evolutionary equilibrium 
has been established between avian host defenses and viral replication, due to a long 
history of evolutionary back and forth.  The disease the virus causes in humans reveals a 
possible relatively recent introduction of the virus to human hosts, which are not adapted 
to sustained viral replication.  Also, influenza A types infecting humans tend to shift 
seasonally and a particular strain does not persist in human hosts. 
Influenzas B and C do not infect avian hosts.  Influenza B is restricted to humans, 
while influenza C is restricted to humans, dogs, and pigs.  Both influenza B and C cause 
disease in their hosts and do not exhibit the equilibrium described above.  Also, the 
absence of influenza B and C from avian hosts may be due to a longer history within the 
human host.
 
Emergence of Highly Pathogenic Avian Influenza 
Avian influenza has recently emerged as a potential influenza pandemic, with the 
sero-type of concern being H5N1.  H5N1 in humans was first observed in Guangdong, 
China in 1996 and Hong Kong in 1997 (Vijaykrishna 2008).  This highly pathogenic 
strain causes a more severe infection, due to a mutation in the HA which allows it to be 
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cleaved by a wider variety of proteases, and thus it is able to infect a wider variety of 
tissues. 
Pathology of H5N1 
 H5N1 infection typically has a 60% fatality rate (Guarner 2009).  Histological 
examination of lung tissues shows inflammation, and the influx of T-lymphocytes and 
macrophages. Lung damage and inflammation are evident, with the attraction of T-
lymphocytes and macrophages.  Pathology can also be observed in bone marrow, spleen, 
kidneys, and liver, with some cases of necrosis in the brain reported.  Alveolar damage is 
characteristic of other more pathogenic influenzas, while spread to other organs is 
common in H5N1 infections, but not infection with other strains of influenzas. 
Cytokine Response to H5N1 
Human Cytokine Response 
In humans, a deregulation of cytokine expression or “cytokine storm” has been 
observed during the H5N1 infectious disease process.  This was first described as a 
possible mechanism of human disease by Cheung and colleagues (2002).  They found 
mRNA levels of IFN- β and TNF-α to be greatly elevated in H5N1-infected human 
macrophages, with some up regulation of RANTES, IL-1β, IL-4, IL-10, IL-12, MIP-1α, 
MIP-1β, and MCP-1.  Chan et al. observed an increase in RANTES, IL-6, IP-10, and 
IFN-β mRNA in alveolar and bronchial epithelial cells infected with H5N1 virus (2005) 
in comparison to cells infected with a H1N1 strain.  This up regulation was confirmed at 
the protein level as well (Chan 2005).  Zeng and colleagues (2007) observed similar 
results when comparing H5N1 virus infection to H3N2 infection.  IL-6 and TNF- up 
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regulation has recently been observed in human astrocytes and other neuronal cells 
following infection with H5N1 virus (Ng 2010). 
Some investigators have explored the idea that the up regulation of certain 
cytokines may contribute to the severity of H5N1 infection.  The effects of TNF- on 
cellular activity have especially been studied, since it is a signal protein involved in 
cellular apoptosis.  The NS protein of H5N1 induces macrophages to produce TNF-α 
(Cheung 2002).  H5N1 infection also activates p38 MAPK (Lee 2005) and TBK-1 (Hui 
2009).  TBK-1 then activates IFN3.  IFN3 and p38 MAPK induce TNF-α expression (Hui 
2009).  H5N1 infection also up regulates TRAIL, which along with TNF-α activates the 
apoptosis pathway (Zhou 2006). 
Rodent Cytokine Response 
Mouse models have been used to study of H5N1 infection/pathogenesis.  In sera 
from H5N1 infected BALB/c mice, an increase in IFN-, TNF-α, IL-1β, and IL-10 were 
observed, with a fluctuation in IL-6 (Evseenko 2007).  Lipatove and colleagues (2005) 
showed that the NS gene was responsible for the increased cytokine expression in 
infected mice.  When they inserted the NS gene of H5N1 into a H1N1 virus, the 
recombinant strain exhibited a higher pathogenicity in mice than the parent H1N1 virus, 
with an increase of IL-1, IL-1, IL-6, GM-CSF, and CXCL1.    Up regulation of IL-1, 
IL-6, and TNF- has also been seen in the brains of H1N1 infected mice (Wang 2008). 
The cotton rat has also been proposed as an influenza model, and it exhibits an 
increase in IL-1, IL-6, TNF-, GRO-, MIP-1, IL-4, and IL-12p40, with a delayed up 
regulation of IFN-, RANTES, IFN-, and IL-10 when challenged with seasonal strains 
of influenza virus (Ottolini 2005).  
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Cytokines and Immunity 
 The increase in cytokine expression with H5N1 infection has led to the 
hypotheses that increased cytokines may contribute to the severity of the disease and 
attempts to control this expression may yield a treatment option.  However, results are 
mixed.  Salomon et al. tested this hypothesis by challenging BALB/c mice that were 
deficient in TNF-, IL-6, or CCL2 with H5N1 virus.  They did not demonstrate any 
decrease in morbidity, which suggests that increased expression of TNF-, IL-6, or 
CCL2 did not contribute to viral pathogenicity (Salomon 2007).  In addition, the use of 
glucocorticoids to suppress cytokines in infected mice did not decrease the pathogenicity 
of the virus.  Szretter and colleagues (2007) using knockout mice for various cytokines, 
confirmed that IL-6 does not affect disease progression (as well as MIP-1), but found 
that the absence of TNF- delayed the onset of weight loss and other symptoms.  
However, the absence of TNF- did not seem to affect viral titres or ultimate mortality.  
They also found that the absence of IL-1 yielded higher titres of virus.  In a more recent 
study, Szretter and colleagues (2009) found that mice deficient in receptors for IFN- or 
IFN- succumbed to disease more rapidly than normal mice.  Furthermore, treating 
murine lung epithelial LA-4 cells with IFN- or IFN- decreased viral replication 
however, there were some strains of H5N1 virus that are able to overcome the interferon 
response. 
Ferret Model Development 
The potential for avian influenza to become a pandemic has created a demand for 
research to characterize the disease and to develop possible vaccines and therapeutics.  
However, the pool of infected humans is low and therefore efficacy research is typically 
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limited to animal models and cell lines.  In such cases, the FDA Animal Rule [21CFR 
314.600-650 (drugs) and 21CFR 601.90-95 (biologicals)] requires that animal models be 
developed to characterize and test possible vaccines or therapeutics to determine efficacy 
against an infection.  Ferrets are a promising model because the disease progression is 
similar to that known in humans (Barnard 2009).  The ferret has been used to characterize 
disease progression at the molecular level with seasonal influenza
 
(Svitek 2008) and 
morbillivirus (Svitek 2007).  Ferrets infected with H5N1 have been shown to have a 
pathogenesis similar to humans, with similar mortalities (Zitzow 2002, Govorkova 2005, 
Maines 2005).  Zitzow, et al. reported upper and lower respiratory tract infection, severe 
lethargy, fever, weight loss, lymphopenia and diarrhea (2002), and Maines, et al. also 
reported inflammation and virus present in the brain.   Successful treatments of ferrets 
infected with H5N1 include Vaxfectin-formulated pDNA vaccines (Lalor 2005), 
oseltamivir (Govorkova 2007), and single- and multiple-clade H5N1 vaccines (Forrest 
2009).   
 
However, reagents are not readily available to characterize avian influenza 
infection at the molecular level in the ferret (Barnard 2009).  Some immunological 
characterization has been performed for H5N1 infection in ferrets using canine 
microarrays showing an upregulation of interferons and CXCL10 (Cameron 2008). 
The objective of this work was to develop molecular reagents for the characterization of 
cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12p40, TNF-α, IFN-α, IFN-β, IFN-γ, TGFB-
β1, and TGFB-β2) in the ferret model of influenza infection and determine cytokine 
mRNA levels in blood and tissues from vaccinated and unvaccinated ferrets.  If the ferret 
response to H5N1 infection is similar to the human response, then an increase in IL-1β, 
IL-4, IL-12p40, IFN-β, and TNF-α (Cheung 2002), an increase in IL-6, and IFN-β in 
 
8 
lungs (Chan 2005), and an increase in IL-6 and TNF-α in brains (Ng 2010) would be 
expected, with such expression being diminished or not observed with ferrets inoculated 
with an efficacious vaccine. 
Materials and Methods 
Reagent Design and Testing 
Ferret DNA Sequences:  All ferret gene sequences for the genes of interest in the NCBI 
database were examined for possible assays as below. The database had one or more 
annotated sequences for IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12p40, TNF-α, IFN-α, IFN-β, 
IFN-γ, TGFB-β1, TGFB-β2, and GAPDH. Those genes that were represented by two or 
more entries in the database were aligned using Vector NTI
®
 Software Version 10.3 
(Invitrogen, Carlsbad, CA). Primers and TaqMan
®
 minor groove binding (MGB) probes 
(Applied Biosystems, Foster City, CA) were designed with Primer Express
®
 Software 
Version 2.0 (Applied Biosystems, Foster City, CA). The default parameters were used for 
MGB assays (primer: Tm 58-60°C, 30-80% GC, 9-40 bases in length; amplicon: Tm 0-
85°C, 50-150 bases in length; TaqMan
®
 MGB probe: Tm 10°C ≥ primers and not 
beginning with G). If possible two quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) assays were designed for each gene targeting the 5′ and 3′ ends. If 
multiple sequences were available for a gene, qRT-PCR assays were designed to target 
conserved regions in the 3′ and 5′ mRNA (Table 1). 
Ferret Peripheral Blood Mononuclear Cells (PBMCs):  Whole blood was obtained from 
35 naive ferrets. PBMCs were isolated from whole blood using a Vacutainer cell 
preparation tube (CPT tube) and stored in CTL wash medium in liquid nitrogen. 
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ConA Stimulation: Cryopreserved ferret PBMC samples were thawed in a 37°C water 
bath and approximately 1x10
6
 cells per well were stimulated in 96-well plates without 
and with 1 µg Concanavalin A (ConA). ConA stimulated PBMC served as a positive 
control to demonstrate cytokine production in response to a known potent mitogen. 
PBMCs were suspended in Compete RPMI (RPMI-1640 + 0.1% Penicillin/Streptomycin 
+ 10% heat-inactivated fetal bovine serum) for overnight culture. After 20 h at 37°C, 5% 
CO2, the stimulated PBMCs, as well as 1x10
6
 unstimulated PBMC, were harvested from 
the wells, washed with Complete RPMI and resuspended in 500 µL of RNALater 
(Ambion, Austin, TX). 
Nucleic Acid Isolation: Total nucleic acid was isolated from the ConA stimulated and 
unstimulated ferret PBMC samples using a bioMérieux NucliSENS
®
 easyMAG™ 
(bioMérieux, Durham, NC) using the manufacturer’s standard protocol. Briefly, 100 µL 
of cells were lysed in easyMAG™  Lysis Buffer for 10 minutes, then magnetic silica was 
added to bind the nucleic acid and incubated for 10 minutes, then the silica was washed 
by the easyMAG™  using easyMAG™  Buffer 1, easyMAG™  Buffer 2, and 
easyMAG™  Buffer 3.  Purified nucleic acid was suspended in a total volume of 100 µL 
of easyMAG™  Buffer 3, and all samples were stored at -20°C. 
RT-PCR reaction:  RT-PCR reactions consisted of 12.5 μL 2X Reaction Mix 
[Deoxyribonucleotide triphosphates (dNTPs), ROX Reference Dye and optimized buffer 
components], 1 μL SuperScript III (SuperScript III Reverse Transcriptase and Platinum
® 
Taq Polymerase) from the SuperScript III Platinum One Step RT-PCR Kit (Invitrogen, 
Carlsbad, CA), 1.25 μL 20X Gene Expression Assay mixture [900 nM forward primer, 
900 nM reverse primer, and 250 nM probe (dual-labeled with FAM™ at the 5′ and a non-
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fluorescent quencher at the 3′ end)], 8.25 µL nuclease-free water, and 2 µL isolated 
nucleic acid in a total volume of 25 µL. Real-time PCR was performed using an ABI 
PRISM
®
 7900HT Fast Sequence Detection System (Applied Biosystems Inc., Foster 
City, CA) with the following conditions: 15 min at 50°C, 2 min at 95°C, followed by 45 
cycles of 95°C for 15 seconds and 60°C for 1 min. All reactions were performed in 
triplicate. Following acquisition, data was analyzed using Version 2.3 of the Sequence 
Detection System Software (Applied Biosystems Inc., Foster City, CA). 
The ΔCT for each mRNA cytokine result was calculated by subtracting the control 
CT from the ConA stimulated CT.  An average of the GAPDH CT was subtracted from the 
ΔCT to normalize the results and calculate the CT CT value.  The mRNA fold change 
was calculated using the formula 2 
ΔCT ΔCT. 
Vaccine Efficacy Testing  
Animal Model: Forty-eight male ferrets (Mustela putorius furo) (Triple F Farms, Sayre 
PA), neutered and de-scented, were placed on study.  The age of animals at Study day 0 
(defined as day of first immunization) was 8-15 weeks (Table 2). Prior to study day 0, 
animals were randomized by weight to four cohorts of 11 animals, plus one extra animal 
per vaccine regimen and one extra animal for the control regimen (a total of four extra 
animals). Extra animals were treated the same as the other cohorts. In the event that an 
animal must be removed from study due to illness prior to challenge, the extra animal 
would undergo challenge, as previously described. During randomization, three animals 
per group were randomly identified to undergo a day 39 sacrifice (4 days post challenge). 
On study day 35, intranasal inoculation of challenge material was conducted on Telazol 
anesthetized ferrets (16-22 mg/kg, intramuscular).  Challenge material (H5N1 strain 
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A/Vietnam/1203/04 target dose of 1 x 10
6 
tissue culture infectious dose 50 (TCID50) in a 
600 l volume) was slowly introduced into the ferret nasal cavity using a 200 L pipettor 
with four 150 L aliquots (alternating nostrils between instillations; each nostril receiving 
a total of two instillations of 150 L each).  Diluent was phosphate buffered saline (PBS) 
without divalent cations.  H5N1 stock material was obtained from the Centers for Disease 
Control and Prevention (CDC) and had previously been tested in mice to characterize the 
virus. 
Vaccinations and Blood Draws:   The three vaccines (Vaccine 1, Vaccine 2, and Vaccine 
3) that were tested were A/Vietnam/1203/04 strain-based, inactivated whole virus 
vaccines, with Vaccine 3 containing an alum adjuvant.  Animals were vaccinated in the 
hip/thigh area, intramuscularly, once on day 0, and again on day 21 (35 days and 14 days 
pre-challenge), on the left and right sides, respectively.  Vaccination was 0.5 mL of 15 
μg/mL (7.5 μg per injection) of vaccine for Groups 1-3 and saline (0.9% NaOCl) for 
Group 4.  Group 1 received Vaccine 1, Group 2 received Vaccine 2, and Group 3 
received Vaccine 3.  Animals were bled on days 0, 35, 38, and 49 (35 days pre-challenge, 
and days 0, 3, and 14 days post challenge). Animals that were found moribund had a 
terminal bleed. One mL of blood was drawn and stored in 2 mL of RNAlater for 
examination of cytokine mRNA levels. 
 
Necropsy and Tissue Collection:  On day 39 (4 days post challenge), three ferrets per 
group were euthanized and underwent full necropsy.  Animals that survived to day 49 (14 
days post challenge) were euthanized. All animals on the day of death (day 39, day 49 or 
moribund) had a gross necropsy performed. Whole blood, liver, brain, and lung (a 1 cm
3
 
portion of three right lung lobes) were taken. The excised pieces were approximately 1 
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cm
3
. Tissues were placed into cryotubes containing 1 mL RNAlater and frozen at <-70ºC 
for examination of cytokine mRNA levels.  
RNA Isolation and Real-time PCR on Samples Collected from Vaccine Efficacy 
Study 
Isolation of RNA was performed using the Qiagen RNA Blood Prep Kit for the blood 
samples and the Qiagen RNA Tissue Kit for tissue samples.  Tissues from ferrets found 
dead were not processed due to the determination that the mRNA in these samples may 
have already degraded significantly and thus yield unreliable results.  Real-time PCR was 
performed as described above using one of each of the cytokine assays, with samples run 
in triplicate for each target. The ΔCT for each cytokine was calculated by subtracting the 
CT from study day 0 from the CT for the respective time points.  The GAPDH ΔCT was 
subtracted from the cytokine ΔCT to normalize the results and calculate the CT CT 
value.  The mRNA fold change was calculated using the formula 2 
ΔCT ΔCT. 
Statistics 
For each gene, the threshold cycles (CTs) recorded for each triplicate 
measurements were averaged by tissue sample type, study day, group, and animal for the 
statistical analysis.  In order to determine if the mean changes from the housekeeping 
gene (GAPDH) were significantly different between the groups, the following analysis of 
variance (ANOVA) model was fitted separately for each gene: 
                                                      Ytdij – GAPDHtdij  =  μ  + groupi + εij  
where Ytdij is the observed CT for the jth animal in group i (i=1 to 5) associated with 
tissue sample type t (t=brain, liver, and lung) on study day d (d=39 and 49), GAPDHtdij is 
the corresponding observed control gene CT for the jth animal in group i, μ is an overall 
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constant, groupi is the effect of group i, and εij is the random error left unexplained by the 
model.  Tukey’s multiple comparisons procedure was also performed in order to 
determine which pairs of groups had mean changes from the housekeeping gene that 
were significantly different than each other.  For blood samples, study day 0 was the 
group against which the fold change was calculated, while for brain, lung, and liver, 
group 5 was the control group. 
Results 
Reagent Design and Testing 
To determine whether the designed real-time PCR assays would be effective, 
ferret PBMCs were thawed and incubated overnight both with and without ConA.  The 
cells were harvested, RNA isolated, and PCR performed with the cytokine primer/probe 
sets.  Table 3 shows the results of each target normalized to GAPDH.  In general, the 
changes in mRNA expression induced by ConA were consistent among the three ferrets 
and the level of expression detected by assays designed to the 5’ end of the transcript was 
similar to 3’ end; however there were some notable exceptions.   
The detection of the 3’ end of IL-2 (IL2_41) was significantly higher in ConA 
stimulated PBMC from two ferrets than the 5’ end (IL2_155).  Eight of the 9 assays in 
the control PBMCs (ferrets 2 and 3) did not detect the IL2_155 target; therefore a fold 
change could not be calculated (Table 2).  In contrast, the IL2_41 assay detected IL-2 in 
the control PBMCs for all three ferrets and showed a 3-4 fold increase in IL-2 induction 
in ConA stimulated PBMCs from all three ferrets.  Possible reasons for the differences in 
the two IL-2 qRT-PCR assays are differences in the efficiency of the amplification due to 
degradation of the 3’ end of the IL-2 gene, alternative splice variants, or a single 
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nucleotide polymorphism (SNP) in either the primer region or probe region. This study 
does not support any one possibility over the other.  IL-8 expression was higher than 
most of the other targets and both IL-8 assays showed similar fold-changes.  The 
detection of the 3’ end of TGFB-1 (TGFB1_324) was higher than for the 5’ end 
(TGFB1_907), with a spike of TGFB1_324 detection for Ferret 3. The detection of the 
3’ end of TGFB-2 (TGFB1_350) was higher than for the 5’ end (TGFB2_1134)   
All of the cytokine genes were induced in PBMCs treated with ConA except IL-
1It is possible that the expression of IL-1was induced by ConA treatment but had 
decreased before the time point of sample collection.  The other targets showed a 
moderate increase in expression, and when two assays to the same cytokine target were 
developed there was a similar increase in expression. 
Assays selected for use in the ferret model were GAPDH_21, IL1_382, IL2_41, 
IL4_7, IL6_492, IL8_160, IFN_25, IFN_39, IFN_97, TNF_187, TGFB1_907, and 
TGFB2_1134. 
Vaccine Testing 
Ferret Groups and Day of Death: 
 The groups that the ferrets were placed into, as well as their days and manner of 
death are in Tables 4 and 5.  All animals survived until at least the day 39 sacrifices (4 
days post challenge), excluding ferrets scheduled for sacrifice on day 39.  All the animals 
that succumbed to disease before day 49 were found dead or euthanized by day 42 (7 
days post challenge).  Group 1 (Vaccine 1) had two animals found dead and five animals 
euthanized before day 49 14 days post-challenge.  Group 2 (Vaccine 2) also had three 
animals found dead, but only two animals euthanized before day 49.  Group 4, the control 
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group, had five animals found dead; with the other three animals dead by day 41 (6 days 
post challenge). 
Cytokine Responses in Blood Samples: 
 Tables 6-17 gives the fold change geometric means for each group and time point 
for each cytokine and the 95% confidence intervals. The data is plotted in Figures 1-12.  
Table 18 gives the ANOVA statistical modeling for each group and cytokine.  A 
summary of the cytokine data is provided in Table 19.   
On day 35 (day of challenge), cytokine expression was similar for each group.  
Most cytokines did not exhibit significant differences in expression between the groups.  
However, IL-1β did exhibit differences in expression, with higher levels in group 1 than 
group 3, and levels in groups 2 and 4 intermediate between groups 1 and 3.  There was a 
trend of large confidence intervals on day 39 for all cytokines except IL-4 and TGFB-1, 
indicating a high variance between animals in the group on that day.  Day 49 results are 
discussed below, however, group 1 only had two animals by day 49, and group 2 only 
had four, so the any differences between the groups may be exaggerated. 
 There were no significant changes in expression in IL-2 (Figure 2) throughout the 
study.  IL-4 expression was not detected in any blood sample (Figure 3).  This may be 
due to low mRNA levels in the final sample, (GAPDH CT values were around 30). 
 IL-1 expression was steady for days 35 and 38 (Figure 1).  By day 39, group 2 
had increased to the highest expression (2 samples), followed by group 1, group 4, and 
group 3, which dropped in expression, with the widest confidence intervals for groups 1, 
3, and 4.  By day 49, expression in groups 2 and 3 were similar to days 35 and 38, while 
group 1 had dropped.  Terminal bloods had a higher level in group 1, with lower 
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expression in groups 2 and 4.  Only day 49 differences were not significant in the 
ANOVA model (Table 18). 
 IL-6 expression was consistent for day 35, but by day 38, expression had 
increased in group 1 and decreased in group 3 (Figure 4).  By day 39 and day 49, 
differences in expression were no longer detected.  Differences in IL-6 levels between the 
groups on day 38 were significant in the ANOVA model (Table 18). 
 IL-8 expression was consistent for groups 1 and 2, throughout the time course.  
Expression in group 3 dropped by day 38 and day 39, but was increased back to day 35 
levels by day 49.  Expression in group 4 dropped slightly lower than group 3 by day 39.  
Terminal samples showed decreased expression in groups 1, 2, and 4.  None of these 
differences were significant in the ANOVA model (Table 18). 
 Expression of IL-12p40 increased on day 39 for groups 1 and 2, but decreased for 
groups 3 and 4.  By day 49, expression levels in groups 2 and 3 recovered to day 35 
levels, while group 1 dropped below day 35 levels.  Terminal blood expression was 
similar to day 39 for groups 1 and 3, but dropped for group 2.  None of these differences 
were significant in the ANOVA model (Table 18). 
 TNF- expression dropped slightly for all groups on day 38, and remained 
constant through day 49.  For terminal samples, expression dropped in groups 2 and 4, 
but not in group 1.  None of these differences were significant in the ANOVA model 
(Table 18). 
 IFN- expression remained level on day 35 and day 39.  By day 39, expression 
for group 2 increased, but no change was observed for the rest of the groups.  By day 49, 
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expression had returned to day 35 levels.  Terminal samples were similar to day 35.   
None of these differences were significant in the ANOVA model (Table 18). 
 IFN- expression increased slightly from day 35 to day 38 for all groups.  By day 
39, expression had dropped slightly for group 4 and increased for groups 1 and 2.  By day 
49, expression had dropped in group 1, but expression was still elevated in group 2.  
Expression in terminal samples dropped in group 4, and less so in group 2, with 
expression in group 1 elevated similar to day 39.  Only the differences in the terminal 
samples were significant in the ANOVA model (Table 18). 
 IFN- expression was similar in all groups on days 35 and 38.  On day 39, 
expression increased in group 2, but was the same for the other groups.  By day 49, 
expression had dropped in group 1, and group 2 had dropped to day 35 levels.  
Expression in terminal samples was decreased slightly for groups 2 and 4 when compared 
to day 35.  None of these differences were significant in the ANOVA model (Table 18). 
 TGFB-1 expression was similar for all groups throughout the time course.  
However, on day 39 expression was slightly elevated in groups 1 and 2.  By day 49, 
expression in group 2 had dropped slightly, and in group 1 a little more.  Expression in 
terminal samples was dropped in group 2, and slightly elevated in group 1 compared with 
day 35.  The differences in days 39 and 49 were significant in the ANOVA model (Table 
18). 
 TGFB-2 expression was similar for all groups on days 35 and 38.  By day 39, 
expression was increased in group 2, and decreased slightly in group 4.  By day 49, 
expression in group 2 had lowered to slightly above day 35, but dropped for group 1.  In 
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terminal samples, expression was low in group 4 similar to day 39, along with group 2.  
None of these differences were significant in the ANOVA model (Table 18). 
Cytokine Responses in Tissue from Ferrets Challenged with H5N1: 
Tables 20-29 give the geometric means of each group and time points for each 
cytokine and their 95% confidence intervals, which are shown graphically in Figures 13-
22.  TGFB-1 and TGFB-2 expression were not calculated, since cytokine data was not 
collected for group 5, which was the baseline for CT calculations.  Table 30 gives the 
ANOVA statistical modeling for each group and cytokine (with summaries for brain, 
liver, and lung in Tables 31, 32, and 33 respectively).  By day 49 expression levels were 
similar for each group for most tissues and cytokines, with exceptions noted below. 
IL-1 expression was similar between days 39 and 49 for both lung and liver, 
while for the brain, expression levels were highest on day 39 in group 4, then group 1, 
and 2, with levels lowest in group 3 (Figure 13).  However, differences in the mean were 
significant for day 49 in the ANOVA model (Table 30). 
IL-2 expression was similar for all three tissues among all the groups and both 
days (Figure 14). However, all differences were significant in the ANOVA model (Table 
30). 
IL-4 expression was varied on day 39 in the lung between animals and groups, but 
was similar on day 49 and in the other tissues (Figure 15).  IL-4 expression was highest in 
group 3, and then decreased in groups 1 and 2, with the lowest levels in group 4.  
However, all differences were significant in the ANOVA model (Table 30). 
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IL-6 expression was similar for all three tissues among all the groups and both 
days (Figure 16. However, all differences were significant in the ANOVA model (Table 
30). 
IL-8 expression in the lung and liver were similar for each group on each day, but 
levels by day 49 had decreased (Figure 17).  However, expression in group 3 in the liver 
did not decrease.  In the brain on day 39, expression was highest in group 4, and then 
decreased in groups 1 and 2, with levels lowest in group 3.  Expression was similar for all 
three tissues among all the groups and both days.  Differences in the brain and lungs on 
both days were significant in the ANOVA model (Table 30). 
IL-12p40 expression was highest in the liver, but consistent between groups and 
days (Figure 18).  In the lung, expression on day 39 was highest in groups 1 and 2 and 
lowest in group 3.  In the brain, expression on day 39 was highest in groups 1 and 4 and 
lowest in group 3.  In the brain and lung, expression dropped in groups 1 and 2 by day 49.  
Expression was similar for all three tissues among all the groups and both days. 
Differences in the brain and lung for both days, and the liver on day 39 were significant 
in the ANOVA model (Table 30). 
TNF- expression was similar for the lung among all groups on both days (Figure 
19).  In the liver and brain on day 39, expression was highest in group 4 and 1 and lowest 
in group 3.  By day 49 in the liver, expression was highest in group 3 and lowest in 
group.  Differences in all tissues for day 39 were significant in the ANOVA model (Table 
30). 
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IFN- expression was similar for all three tissues among all the groups and both 
days (Figure 20). However, all differences were significant in the ANOVA model (Table 
30). 
IFN- expression was highest in the brain, but in the brain it was consistent 
between groups and both days (Figure 21).  In the lung on day 39, expression was highest 
in groups 1 and 2, and lowest in group 3.  By day 49, levels in groups 1 and 2 had 
decreased.  In the liver, expression was highest in group 4, then decreases in groups 1 and 
2, and was lowest in group 3.  All differences were significant in the ANOVA model 
(Table 30). 
IFN- expression in the lung on day 39 was highest in group 2, then decreased in 
groups 1 and 4, and was lowest in group 3 (Figure 22).  By day 49, levels in groups 1 and 
2 had IFN- levels decreased to the level of group 3.  Expression in the liver on day 39 
was highest in groups 1 and 4 and lowest in groups 2 and 3.  By day 49, levels in groups 
1 and 2 had dropped below group 3.  In the brain, expression was similar between all 
groups on both days.  Differences in the brain and lung on both days were significant in 
the ANOVA model (Table 30). 
TGFB-1 and TGFB-2 results were not graphed, since expression levels were 
not obtained for the group 5 tissues, and thus 2 
ΔCT ΔCT  values could not be calculated.  
However, only expression of TGFB-1 in the liver on day 39 and TGFB-2 in the lung 
on day 39 were significantly different in the ANOVA model (Table 30). 
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Conclusions   
Vaccine Efficacy 
  Ferrets inoculated with Vaccine 3 had 100% survival, with survival rates of 33% 
with Vaccine 2 and 22% with Vaccine 1.  Vaccine 3 contained alum as an adjuvant, 
which is an effective adjuvant in increasing the immune response of the vaccine. As 
expected there were no survivors in Group 4, the saline control group, demonstrating that 
H5N1 at the challenge dose was lethal in ferrets.  
Ferret Cytokine Expression  
Post challenge with H5N1 influenza, Group 1 showed an increase in IL-2, IL-6, 
IL-12p40, and IFN-β, and a decrease in TNF-α in the blood, an increase in IL-1β and 
TNF-α in the brain, an increase of IFN-β and IFN-γ in the lung, and an increase of IFN-γ 
in the liver.  Group 2 showed an increase in IL-2, IL-12p40, IFN-α, IFN-β, IFN-γ, and 
TGFB-β2, and a decrease in TNF-α in the blood, an increase of IL-1β in the brain, an 
increase of IFN-β and IFN-γ in the lung, and no alteration of cytokine levels in the liver.  
Group 3 showed a decrease in IL-2, IL-6, IL-8, IL-12p40, and TNF-α in the blood, little 
variance of cytokine levels in the brain and liver, and an increase in IL-4 in the lung.  
Group 4, the saline control group, showed an increase in IL-2, and a decrease in IL-
12p40, TNF-α and IFN-β in the blood, an increase of IL-1β, IL-8 and TNF-α in the brain, 
an increase of an increase of IFN-β and IFN-γ in the lung, and an increase of TNF-α and 
IFN-γ in the liver. 
In the blood, the most variation in cytokine expression was observed at day 39 
(four days after H5N1 challenge).  Days 35 and 38 did not show significant alteration in 
cytokine expression suggesting that the disease may not yet affected the immune system 
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to a level that elicited a cytokine response.  However, between challenge and day 39 
showed some initial changes in cytokine expression were observed.  On day 39, there was 
some variation in cytokine expression.  Generally, Groups 1 and 2 showed higher 
expression of cytokines than Groups 3 and 4 (Figures 1-12). In general, Group 4 showed 
the lowest expression.  This suggests that cytokine levels were modulated by the vaccines 
with partial efficacy, while the control group showed decreased or unaltered cytokine 
expression.  Vaccines 1 and 2 may have induced sufficient immunity to delay the 
cytokine storm, resulting in delayed death in the animals   However, since the ANOVA 
model did not show much significance in the differences between groups, these 
conclusions cannot be stated with full confidence.  
An interesting note was cytokine expression on day 39 in all the tissue samples.  
The expression in group 4 animals varied greatly in almost all tissues for almost all 
cytokines, with brain showing the greatest variation in cytokine expression (Figures 13-
22).  This may be indicative of disregulation of cytokine expression which is thought to 
contribute to the cytokine storm.  Some of this variance was also observed in for the other 
groups, especially in the lungs for IL-4, IL-12p40, and IFN-.  The liver appears to have 
the least variance in cytokine expression, however, the expression of cytokines in Group 
4 still varied on day 39.  For all tissues and cytokines, expression levels returned to near 
baseline levels by day 49.   
Previous studies have shown higher cytokine expression in mice by day 3 post 
challenge with increases persisting for nine days (Evseenko 2007, Lipatov 2005). In 
humans, H5N1 infection results in an increase in IL-1β, IL-4, IL-12p40, IFN-β, and TNF-
α (Cheung 2002), an increase in IL-6, and IFN-β in lung (Chan 2005), and an increase in 
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IL-6 and TNF-α in brain (Ng 2010). Similar alterations in cytokine gene expression were 
not observed in the present study.  We observed decreased expression of IL-12p40, TNF-
α and IFN-β in the blood and an increase in IL-2, although these results were not 
statistically significant.  There are several potential explanations for the differences 
observed. An issue with this study is that it was performed within the confines of another 
study, with different aims and objectives, thereby limiting sample availability.  There 
were no naïve ferrets as a control for the blood samples.  Also, the number of ferrets by 
day 49 was very low for Groups 1 and 2, and thus any differences between them and 
Group 3 were not statistically significant.  This may have resulted in an incomplete 
picture of cytokine expression in ferrets infected with H5N1, and those treated with the 
vaccines. 
This study would have benefited not only from additional timepoints but also 
more blood per timepoint. Optimally 1-2 mL of blood would be required to isolate 
sufficient RNA from the blood.  This would also have allowed the use of the PAXgene 
kit (or similar kit) which is designed for RNA preservation in blood samples, but requires 
at minimum 1 mL of blood.  The manufacturer of RNAlater cautions against the use of 
their product for whole blood, the use of which may have decreased the yield of mRNA.  
A more complete picture may have been obtained if timepoints occurred more often, even 
every six hours for at least 9 days.  In cell lines, expression spikes between six and 24 
hours (Cheung 2002, Chan 2005, Ng 2010), but in mouse models, spikes are seen 
between six and nine days (Evseenko 2007, Lipatov 2005).  Data from blood drawn every 
six hours would help in determining to the kinetics of cytokine gene expression.  Also, it 
would be beneficial in the elucidation of the model to have more blood and tissue sample 
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from earlier times post-challenge, perhaps at the same time points as the blood for 
comparison.  Terminal data for tissues on non-scheduled sacrifice days were not collected 
because ferret necropsies on animals found dead or euthanized outside of the scheduled 
day 39 and day 49 sacrifices were not performed immediately.  Immediate necropsies 
would have been beneficial for mRNA integrity, and may have yielded interesting results. 
In summary, more frequent time points (every six hours) with increased amounts 
of blood would provide additional insight into the alterations in cytokine gene expression 
in both tissues and blood in the ferret model of highly pathogenic avian influenza.  Future 
studies would include additional time points and scheduled sacrifices between day 35 and 
38 to further define the time course of cytokine gene expression. 
Further Experiments 
The expression of additional cytokines is also up regulated during H5N1 infection 
in other species, primarily RANTES, MIP-1, MCP-1, GM-CSF, and CXCL1 (Chan 
2005 and Wang 2008).  Other studies could be performed, to examine these cytokines, 
but sufficient sample would be required.  Combining the results of a study such as this 
and the results of this thesis as well as future work based upon it could result in the 
elucidation of cytokine expression to characterize the immunological effects of H5N1 
and other influenza infections such as the 2009 H1N1 influenza virus. 
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IL-4_7 21 59 52 CTCACCTCCCAACTGATTCCA 81 52 
IL4_29_MGB 18 68 50 CTCTGGTCTGCTTACTAG     
IL4_67 20 59 55 GGATGAAAGTGCCGGTGAGT     
IL4_250 21 58 48 TGCTCCAACAGATTGCTCAGA 80 49 
IL4_273_MGB 16 70 50 ACTTCACAGGAACCTC     
IL4_312 22 58 45 ACAGGTCATGTTTGCCATGTTC     
              
GAPDH_738 20 58 50 CCTGGAGAAAGCTGCCAAAT 80 50 
GAPDH_759_MGB 18 68 39 TGATGACATCAAGAAGGT     
GAPDH_797 20 59 60 CCCTCTGATGCCTGCTTCAC     
GAPDH_21 18 58 56 CGGATTTGGCCGTATTGG 81 53 
GAPDH_42_MGB 15 70 73 CCTGGTCACCAGGGC     
GAPDH_88 28 59 36 
CGACAATATCCACTTTACCAGAGT
TAAA     
              
IFN_365 20 59 45 CAGCGCAAAGCGATAAATGA 76 40 
IFN_386_MGB 19 69 37 CTCATCAAAGTGATGAATG     
IFN_432 27 59 41 
TTCCTTAGGTTAGATCTTGGTGAGA
GA     
IFN_97 25 58 40 
TGCAAGTAATCCAGATGTAGCAGA
T 77 43 
IFN_124_MGB 15 69 47 TGGGCCTCTTTTCTT     
IFN_166 27 58 41 
CTCCTCTCTCCAGTTCTTCAAAATA
TC     
              
IFN_25 20 60 60 TCACCTGCTCCCTGGAACAC 66 84 
IFN_51 17 69 53 CCTGGAGGAATTGTGCT     
IFN_90 20 59 60 GCCCAGCTGCTCAGAAAGTC     
              
IFN_39 23 58 43 ATATTTCTCCACCACGGTTCTTG 77 43 
IFN_63_MGB 25 69 32 CATGAACTATAACTTACTTCGATTC     
IFN_110 22 59 50 TCCACACTGCTGCTGCTTAGTT     
              
TNF_187 20 60 60 CCTCTGGCCCAGACAGTCAA 80 49 
TNF_208_MGB 17 69 47 TCATCTTCTCGAACTCC     
TNF_249 24 58 46 AACATGAGCTACAGGCTTGTCACT     
IL6_492 20 60 60 CCCCGACCCTACCACAGATT 84 60 
IL6_516_MGB 13 69 69 CCTGCAGGCTCTC     
IL6_549 20 58 55 CCACTTGTCCTGCGACTTGA     
Table 1. (Continued) 
Tm – Melting Temperature 
%CG – Percentage of guanine and cytosine in amplicon 
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IL8_8 22 59 50 CAGGAAGAAACCAGACCAAAGG 80 50 
IL8_31_MGB 17 68 41 ACCTTGCATCAACATGA     
IL8_67 19 58 53 AGCAACAGCCAGCTTGGAA     
IL8_160 18 59 61 CCACTCCACGCCTTTCCA 79 48 
IL8_179_MGB 19 68 32 CCCAAATATATCAAAGAAC     
IL8_220 21 59 52 TGGGCCACTGTCAATCACTCT     
              
IL1_382 24 59 38 TTCCAGGACATAAACCAAAAATCC 79 48 
IL1_407_MGB 16 69 44 TGGTGCTGTATAACTC     
IL1_441 18 59 61 GAGCGCCCGAAGCTCATA     
IL1_24 26 58 42 
CAGTGAAGTGATGTCTTATGGCTA
CA 77 43 
IL1_51_MGB 17 68 41 TGACAATGAGAATGACC     
IL1_90 22 59 45 AGGACCATCAGCCTCAAAGAAA     
              
TGFB2_50 18 60 67 CCGCGCTCAGCCTGTCTA 85 61 
TGFB2_69_MGB 13 68 69 CTGCAGCACGCTC     
TGFB2_103 20 60 50 TGCGCATGAACTGGTCCATA     
TGFB2_1134 21 59 48 TTGCTGTGTGTCCCAGGATTT 80 50 
TGFB2_1159_MGB 14 68 57 CCGCTCACCATTCT     
TGFB2_1195 20 58 55 TGGGTGTCTTGCCGATGTAG     
              
TGFB1_324 18 59 61 CACCCGCGTGCTAATGGT 79 48 
TGFB1_348_MGB 17 70 41 CACCAACAGAATCTATG     
TGFB1_385 20 58 45 GCGGGCTTTTCTTGATTTTG     
TGFB1_907 20 59 55 CGTAAGGATCTGGGCTGGAA 83 57 
TGFB1_928_MGB 16 69 63 TGGATCCACGAGCCCA     
TGFB1_967 20 60 50 GGCAGAAATTGGCGTGGTAA     
              
IL2_41 20 58 50 TCGCACTCTTCGCAAACAGT 80 49 
IL2_64_MGB 17 68 47 CCTACTACTTCAAGCTC     
IL2_101 20 58 50 TGTTGCTGTGCTTCCTTCGT     
IL2_155 19 58 58 ATGAGAGCCCCAGGATGCT 79 47 
IL2_176_MGB 20 70 40 CGTTTAAATTCTACATGCCC     
IL2_220 24 60 46 GATGAGTCAATTCTGTGGCCTTCT     
Table 1. Targeted Sequences in Selected Ferret Cytokine Genes. 
Tm – Melting Temperature 
%CG – Percentage of guanine and cytosine in amplicon 
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 CTCT Fold Change (2 
ΔCT ΔCT) 
 PCR Assay Ferret 1 Ferret 2 Ferret 3 Ferret 1 Ferret 2 Ferret 3 
IL1_24 2.6 2.1 1.2 0.2 0.2 0.4 
IL1_382 1.4 0.5 -0.2 0.4 0.7 1.2 
IL2_41 -1.6 -2.0 -1.8 3.1 4.0 3.4 
IL2_155 -5.5 NA NA 44.0 NA NA 
IL4_7 -2.5 -3.1 -2.8 5.8 8.5 7.0 
IL4_250 -2.2 -2.9 -2.5 4.7 7.3 5.6 
IL6_492 -2.2 -2.6 -2.1 4.6 6.0 4.2 
IL8_8 -4.0 -5.3 -5.1 16.3 38.3 35.0 
IL8_160 -4.1 -5.1 -5.6 16.8 35.4 49.7 
TNF_187 -2.5 -5.2 -4.1 5.6 35.9 17.0 
IFN_25 -1.9 -2.5 -2.0 3.7 5.5 3.9 
IFN_39 -2.7 -2.6 -2.5 6.7 5.9 5.8 
IFN_97 -2.2 -2.5 -2.1 4.7 5.5 4.4 
IFN_365 -1.6 -2.1 -2.1 3.1 4.4 4.2 
TGFB1_324 -1.2 -4.5 -8.8 2.3 23.1 452.2 
TGFB1_907 -1.3 -2.8 -3.6 2.5 6.7 12.4 
TGFB2_50 -4.6 -6.3 -6.3 24.2 80.2 79.4 
TGFB2_1134 -2.1 -2.5 -2.3 4.3 5.7 4.9 
Table 2. Cytokine Induction in Ferret PBMCs following Stimulation with ConA. 
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Table 3. Ferret Vaccine Experimental Design.
 
1
ROA—Route of Administration; IM--intramuscular 
2
49/t—Day 49 or terminal draw sample if animal is euthanized prior to Day 49. 
3
Three unchallenged ferrets from another study were used as baselines for tissue cytokine 
analysis.  TGFB-1 and TGFB-2 data were not collected for that study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Vaccination   
Cohort Vaccine 
Vaccine 
Dose 
ROA
1 
Days 
Challenge 
Day 35 
Blood Draw
2
 
1 Vaccine 1 7.5 μg IM 0, 21 A/VN/1203/04 
0, 35, 38, 39,  
49/t 
2 Vaccine 2 7.5 μg IM 0, 21 A/VN/1203/04 
0, 35, 38, 39, 
49/t 
3 
Vaccine 3 
(contained alum 
adjuvant) 
7.5 μg IM 0, 21 A/VN/1203/04 
0, 35, 38, 39, 
49/t 
4 Saline control NA IM 0, 21 A/VN/1203/04 
0, 35, 38, 39, 
49/t 
5 None
3
 NA NA NA NA NA 
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Group  % Survival for Day Post Challenge 
 Day 4 Day 6 Day7 Day 8 Day 9 Day 14 
1.0 88.9 55.6 22.2 22.2 22.2 22.2 
2.0 100 66.7 55.6 44.4 33.3 33.3 
3.0 100 100 100 100 100 100 
4.0 75.0 50.0 0    
Table 4. Ferret Survival Post-Challenge with H5N1. 
All treatments were on Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 
was treated with Vaccine 1, Group 2 was treated with Vaccine 2, Group 3 was treated 
with Vaccine 3, and Group 4 was treated with a saline control.  Challenge with H5N1 
virus was on Day 35.  For each group, three animals were scheduled for euthanasia on 
Day 39 (4 days post challenge). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
Animal 
ID  Cohort Sacrifice 39 Extras 
Animal Death 
Date 
Euthanized or Found 
Dead 
1002 1 No No Day 42 EUTHANIZED 
1000 1 No No Day 41 EUTHANIZED 
1163 1 No No Day 42 EUTHANIZED 
1031 1 No No Day 49 EUTHANIZED 
1019 1 No No Day 39 FOUND DEAD 
1033 1 No No Day 41 FOUND DEAD 
1013 1 No No Day 41 EUTHANIZED 
1010 1 No No Day 42 EUTHANIZED 
991 1 Yes No Day 39 EUTHANIZED 
995 1 Yes No Day 39 EUTHANIZED 
1020 1 Yes No Day 39 EUTHANIZED 
1014 1 No Yes Day 49 EUTHANIZED 
996 2 No No Day 41 EUTHANIZED 
1001 2 No No Day 42 FOUND DEAD 
1024 2 No No Day 41 EUTHANIZED 
1162 2 No No Day 49 EUTHANIZED 
994 2 No No Day 49 EUTHANIZED 
1023 2 No No Day 49 EUTHANIZED 
1035 2 No No Day 41 FOUND DEAD 
1016 2 No No Day 43 FOUND DEAD 
998 2 Yes No Day 39 EUTHANIZED 
1022 2 Yes No Day 39 EUTHANIZED 
1027 2 Yes No Day 39 EUTHANIZED 
1026 2 No Yes Day 49 EUTHANIZED 
1003 3 No No Day 49 EUTHANIZED 
993 3 No No Day 49 EUTHANIZED 
997 3 No No Day 49 EUTHANIZED 
992 3 No No Day 49 EUTHANIZED 
1028 3 No No Day 49 EUTHANIZED 
1009 3 No No Day 49 EUTHANIZED 
1025 3 No No Day 49 EUTHANIZED 
1030 3 No No Day 49 EUTHANIZED 
1161 3 Yes No Day 39 EUTHANIZED 
1029 3 Yes No Day 39 EUTHANIZED 
1021 3 Yes No Day 39 EUTHANIZED 
1004 3 No Yes Day 49 EUTHANIZED 
 
Table 5.  Days of Death in Ferrets Vaccinated with One of Three Candidate 
Vaccines or Buffer Control. 
All treatments were on Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 
was treated with Vaccine 1, Group 2 was treated with Vaccine 2, Group 3 was treated 
with Vaccine 3, and Group 4 was treated with a saline control.  Challenge with H5N1 
virus was on Day 35.  For each group, three animals were scheduled for euthanasia on 
Day 39. 
 
 
 
31 
Animal 
ID  Cohort Sacrifice 39 Extras 
Animal Death 
Date 
Euthanized or Found 
Dead 
1007 4 No No Day 41 EUTHANIZED 
999 4 No No Day 41 EUTHANIZED 
1006 4 No No Day 40 FOUND DEAD 
1017 4 No No Day 39 FOUND DEAD 
1005 4 No No Day 39 EUTHANIZED 
1018 4 No No Day 40 FOUND DEAD 
1012 4 No No Day 41 FOUND DEAD 
1032 4 No No Day 41 EUTHANIZED 
1008 4 Yes No Day 39 FOUND DEAD 
990 4 Yes No Day 39 EUTHANIZED 
1011 4 Yes No Day 39 EUTHANIZED 
 
Table 5 (Continued). 
All treatments were on Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 
was treated with Vaccine 1, Group 2 was treated with Vaccine 2, Group 3 was treated 
with Vaccine 3, and Group 4 was treated with a saline control.  Challenge with H5N1 
virus was on Day 35.  For each group, three animals were scheduled for euthanasia on 
Day 39. 
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Table 6.  Fold-change in IL-1β mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% 
Confidence Interval) 
Vaccine 1 1 
35 0 10 0.35 (0.24, 0.52) 
38 3 10 0.30 (0.16, 0.57) 
39 4 3 0.27 (0.08, 0.90) 
49 14 1 0.08 ( -- ) 
Terminal NA 4 0.51 (0.15, 1.73) 
Vaccine 2 2 
35 0 11 0.19 (0.08, 0.43) 
38 3 11 0.20 (0.12, 0.32) 
39 4 2 0.73 (0.00, 4378.74) 
49 14 4 0.28 (0.04, 2.06) 
Terminal NA 2 0.05 (0.00, 47010.65) 
Vaccine 3 3 
35 0 11 0.07 (0.04, 0.11) 
38 3 11 0.07 (0.03, 0.12) 
39 4 3 0.04 (0.00, 0.66) 
49 14 8 0.17 (0.06, 0.47) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 0.21 (0.12, 0.38) 
38 3 11 0.38 (0.22, 0.66) 
39 4 2 0.14 (0.01, 3.15) 
49 14 NA NA 
Terminal NA 4 0.08 (0.01, 0.58) 
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.45 (0.69, 3.08) 
38 3 10 4.90 (2.48, 9.68) 
39 4 3 11.18 (0.534, 233.89) 
49 14 1 2.19 ( -- ) 
Terminal NA 4 6.00 (2.04, 17.66) 
Vaccine 2 2 
35 0 11 2.17 (0.67, 7.05) 
38 3 11 4.55 (1.52, 13.60) 
39 4 2 5.64 (0.00, 2778872.19) 
49 14 4 4.81 (0.35, 65.69) 
Terminal NA 2 5.59 (0.00, 23641708602) 
Vaccine 3 3 
35 0 11 3.58 (1.55, 8.26) 
38 3 11 2.85 (1.00, 8.07) 
39 4 3 1.96 (0.02, 176.80) 
49 14 8 5.33 (1.19, 23.93) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 1.74 (1.00, 3.01) 
38 3 11 2.55 (1.13, 5.80) 
39 4 2 1.30 (0.09, 18.28) 
49 14 NA NA 
Terminal NA 4 0.82 (0.01, 59.22) 
 
Table 7.   Fold Change IL-2 mRNA Levels in Whole Blood from Ferrets Challenged 
with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 2.19 (0.91, 5.24) 
38 3 10 6.29 (2.76, 14.34) 
39 4 3 12.17 (4.35, 34.03) 
49 14 1 2.46 ( -- ) 
Terminal NA 4 7.98 (0.87, 73.56) 
Vaccine 2 2 
35 0 10 2.21 (0.89, 5.50) 
38 3 11 4.99 (2.40, 10.36) 
39 4 2 7.34 (0.10, 566.16) 
49 14 4 10.26 (3.67, 28.66) 
Terminal NA 2 3.66 (1.59, 8.45) 
Vaccine 3 3 
35 0 9 2.22 (0.71, 6.97) 
38 3 11 4.83 (1.61, 14.45) 
39 4 3 5.76 (1.90, 17.42) 
49 14 8 6.48 (2.47, 16.95) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 9 1.31 (0.67, 2.57) 
38 3 11 4.16 (1.79, 9.67) 
39 4 2 2.58 (0.19, 34.70) 
49 14 NA NA 
Terminal NA 4 0.49 (0.06, 3.86) 
 
Table 8.   Fold Change IL-4 mRNA Levels in Whole Blood from Ferrets Challenged 
with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.44 (0.73, 2.82) 
38 3 10 3.93 (2.16, 7.15) 
39 4 3 2.91 (0.05, 164.77) 
49 14 1 1.13 ( -- ) 
Terminal NA 4 3.55 (0.86, 14.63) 
Vaccine 2 2 
35 0 11 1.79 (1.08, 2.96) 
38 3 11 2.01 (0.80, 5.03) 
39 4 2 3.30 (0.00, 421288.79) 
49 14 4 1.67 (0.59, 4.69) 
Terminal NA 2 1.48 (0.00, 2145.55) 
Vaccine 3 3 
35 0 11 2.06 (0.75, 5.61) 
38 3 11 0.71 (0.21, 2.43) 
39 4 3 1.41 (0.04, 46.66) 
49 14 8 2.52 (0.49, 13.00) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 1.35 (0.42, 4.32) 
38 3 11 2.00 (0.98, 4.08) 
39 4 2 1.54 (0.15, 15.66) 
49 14 NA NA 
Terminal NA 4 0.43 (0.01, 20.74) 
 
Table 9.   Fold Change IL-6 mRNA Levels in Whole Blood from Ferrets Challenged 
with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
 
36 
 
Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.75 (1.20, 2.55) 
38 3 10 2.76 (1.83, 4.15) 
39 4 3 3.17 (0.41, 24.37) 
49 14 1 2.06 ( -- ) 
Terminal NA 4 1.79 (0.50, 6.37) 
Vaccine 2 2 
35 0 11 2.14 (1.45, 3.15) 
38 3 11 1.98 (1.45, 2.70) 
39 4 2 2.91 (0.08, 106.16) 
49 14 4 2.88 (1.18, 7.05) 
Terminal NA 2 0.98 (0.27, 3.58) 
Vaccine 3 3 
35 0 11 1.57 (0.71, 3.45) 
38 3 11 1.04 (0.50, 2.18) 
39 4 3 1.38 (0.15, 13.00) 
49 14 8 2.45 (1.04, 5.78) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 2.43 (1.11, 5.35) 
38 3 11 3.04 (1.34, 6.77) 
39 4 2 1.02 (0.01, 126.18) 
49 14 NA NA 
Terminal NA 4 1.65 (0.18, 14.73) 
 
Table 10.   Fold Change IL-8 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 3.13 (1.29, 7.59) 
38 3 10 10.87 (2.16, 54.71) 
39 4 3 19.65 (0.14, 2761.67) 
49 14 1 1.23 ( -- ) 
Terminal NA 4 31.37 (2.29, 429.54) 
Vaccine 2 2 
35 0 11 4.21 (1.59, 11.15) 
38 3 11 5.82 (1.75, 19.36) 
39 4 2 30.13 (0.00, 770391479.24) 
49 14 4 13.86 (2.00, 96.00) 
Terminal NA 2 4.28 (0.00, 1187498200000) 
Vaccine 3 3 
35 0 11 5.19 (1.58, 17.01) 
38 3 11 2.28 (0.38, 13.81) 
39 4 3 3.83 (0.06, 229.10) 
49 14 8 11.92 (1.53, 92.99) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 4.13 (0.77, 22.28) 
38 3 11 5.22 (1.44, 18.93) 
39 4 2 3.65 (0.00, 274937.54) 
49 14 NA NA 
Terminal NA 4 4.38 (0.15, 127.34) 
 
Table 11.   Fold Change IL-12p40 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.65 (1.05, 2.58) 
38 3 10 0.61 (0.30, 1.25) 
39 4 3 0.52 (0.05, 5.78) 
49 14 1 1.04 ( -- ) 
Terminal NA 4 0.58 (0.21, 1.64) 
Vaccine 2 2 
35 0 11 1.23 (0.68, 2.21) 
38 3 11 0.50 (0.26, 0.93) 
39 4 2 0.82 (0.20, 3.42) 
49 14 4 0.87 (0.56, 1.37) 
Terminal NA 2 0.18 (0.00, 160.63) 
Vaccine 3 3 
35 0 11 0.88 (0.40, 1.93) 
38 3 11 0.59 (0.35, 1.01) 
39 4 3 0.49 (0.17, 1.36) 
49 14 8 0.82 (0.39, 1.71) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 1.23 (0.72, 2.12) 
38 3 11 0.92 (0.52, 1.61) 
39 4 2 1.17 (0.06, 24.34) 
49 14 NA NA 
Terminal NA 4 0.23 (0.08, 0.68) 
 
Table 12.   Fold Change TNF-α mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 0.78 (0.24, 2.53) 
38 3 10 1.21 (0.23, 6.46) 
39 4 3 1.54 (0.00, 1009.03) 
49 14 1 0.17 ( -- ) 
Terminal NA 4 3.47 (0.09, 134.14) 
Vaccine 2 2 
35 0 11 1.07 (0.42, 2.72) 
38 3 11 1.53 (0.25, 9.42) 
39 4 2 18.94 (0.0000, 682698868806) 
49 14 4 1.85 (0.17, 20.51) 
Terminal NA 2 1.12 (0.00, 1.2603276E14) 
Vaccine 3 3 
35 0 11 0.85 (0.21, 3.44) 
38 3 11 0.27 (0.04, 2.09) 
39 4 3 0.55 (0.00, 1950.14) 
49 14 8 2.22 (0.14, 35.59) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 0.89 (0.13, 6.17) 
38 3 11 1.04 (0.24, 4.52) 
39 4 2 0.66 (0.00, 1418.92) 
49 14 NA NA 
Terminal NA 4 0.49 (0.00, 171.11) 
 
Table 13.   Fold Change IFN-α mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.25 (0.49, 3.19) 
38 3 10 4.08 (1.64, 10.16) 
39 4 3 9.62 (2.42, 38.26) 
49 14 1 0.63 ( -- ) 
Terminal NA 4 5.11 (0.49, 53.72) 
Vaccine 2 2 
35 0 11 1.69 (0.80, 3.56) 
38 3 11 3.21 (1.35, 7.64) 
39 4 2 8.29 (0.00, 32189.94) 
49 14 4 7.66 (6.34, 9.25) 
Terminal NA 2 1.66 (0.00, 87915.48) 
Vaccine 3 3 
35 0 11 1.60 (0.46, 5.50) 
38 3 11 2.41 (0.66, 8.78) 
39 4 3 3.18 (0.22, 44.96) 
49 14 8 4.27 (1.14, 16.00) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 1.41 (0.67, 3.00) 
38 3 11 3.00 (1.30, 6.91) 
39 4 2 1.57 (0.00, 12676.24) 
49 14 NA NA 
Terminal NA 4 0.42 (0.03, 5.53) 
 
Table 14.   Fold Change IFN-β mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 0.89 (0.51, 1.53) 
38 3 10 1.36 (0.36, 5.20) 
39 4 3 1.31 (0.03, 64.45) 
49 14 1 0.05 ( -- ) 
Terminal NA 4 2.19 (0.05, 87.46) 
Vaccine 2 2 
35 0 11 1.02 (0.62, 1.67) 
38 3 11 1.07 (0.2688, 4.2258) 
39 4 2 17.21 (0.00, 24195275699) 
49 14 4 2.73 (0.61, 12.16) 
Terminal NA 2 0.26 (0.00, 3508836.98) 
Vaccine 3 3 
35 0 11 0.49 (0.18, 1.32) 
38 3 11 0.52 (0.17, 1.62) 
39 4 3 0.61 (0.01, 41.09) 
49 14 8 1.44 (0.31, 6.62) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 0.65 (0.21, 2.03) 
38 3 11 0.85 (0.38, 1.92) 
39 4 2 0.44 (0.00, 80.95) 
49 14 NA NA 
Terminal NA 4 0.47 (0.05, 4.23) 
 
Table 15.   Fold Change IFN-γ mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 1.13 (0.70, 1.81) 
38 3 10 0.71 (0.43, 1.16) 
39 4 3 1.43 (0.67, 3.04) 
49 14 1 0.47 ( -- ) 
Terminal NA 4 1.21 (0.46, 3.15) 
Vaccine 2 2 
35 0 11 1.09 (0.821, 1.44) 
38 3 11 0.89 (0.60, 1.33) 
39 4 2 2.01 (0.67, 6.03) 
49 14 4 1.32 (1.07, 1.62) 
Terminal NA 2 0.09 (0.00, 1.7753446E13) 
Vaccine 3 3 
35 0 11 1.28 (0.77, 2.12) 
38 3 11 0.78 (0.51, 1.18) 
39 4 3 1.10 (0.37, 3.26) 
49 14 8 0.79 (0.49, 1.29) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 0.97 (0.56, 1.70) 
38 3 11 0.59 (0.36, 0.95) 
39 4 2 0.76 (0.38, 1.51) 
49 14 NA NA 
Terminal NA 4 0.40 (0.14, 1.15) 
 
Table 16.   Fold Change TGFB-β1 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Treatment Group 
Study 
Day 
Day Post-
Challenge 
N 
Geometric Mean (95% Confidence 
Interval) 
Vaccine 1 1 
35 0 10 0.85 (0.47, 1.54) 
38 3 10 1.43 (0.41, 4.96) 
39 4 3 2.15 (0.19, 24.85) 
49 14 1 0.06 ( -- ) 
Terminal NA 4 3.95 (0.22, 71.30) 
Vaccine 2 2 
35 0 11 1.14 (0.53, 2.45) 
38 3 11 1.24 (0.36, 4.26) 
39 4 2 19.34 (0.00, 2713578355.1) 
49 14 4 4.98 (0.58, 42.44) 
Terminal NA 2 0.52 (0.00, 330585430.08) 
Vaccine 3 3 
35 0 11 0.45 (0.16, 1.22) 
38 3 11 0.55 (0.16, 1.86) 
39 4 3 0.65 (0.00, 156.99) 
49 14 8 1.74 (0.28, 10.66) 
Terminal NA NA NA 
Saline 
control 
4 
35 0 11 0.83 (0.20, 3.43) 
38 3 11 1.53 (0.46, 5.08) 
39 4 2 0.27 (0.00, 48.86) 
49 14 NA NA 
Terminal NA 4 0.36 (0.01, 21.04) 
 
Table 17.   Fold Change TGFB-β2 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1. 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Cytokine 
Study 
Day 
Group Effect 
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
Tukey's P-Value 
#
 
IL-1β 
0 0.00* 
0.41 (1<3) 0.01 
2.37 (3>4) 0.01 
35 0.04* 2.41 (1>3) 0.03 
38 0.02* 0.41 (3<4) 0.02 
39 0.05*  
49 0.52  
Terminal 0.03* 6.11 (1>4) 0.03 
IL-2 
0 0.79  
35 0.36  
38 0.34  
39 0.84  
49 0.75  
Terminal 0.07  
IL-4 
0 0.26  
35 0.78  
38 0.65  
39 0.85  
49 0.56  
Terminal 0.02* 11.04 (1>4) 0.02 
IL-6 
0 0.95  
35 0.74  
38 0.01* 4.05 (1>3) 0.01 
39 0.60  
49 0.22  
Terminal 0.06  
IL-8 
0 0.42  
35 1.00  
38 0.13  
39 0.83  
49 0.43  
Terminal 0.42  
IL-12p40 
0 0.92  
35 0.65  
38 0.29  
39 0.53  
49 0.85  
Terminal 0.28  
 
Table 18.  Results of ANOVA Models Fitted to     for Cytokine Gene Expression in 
Whole Blood from Ferrets Challenged with H5N1. 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine 
Study 
Day 
Group Effect 
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
Tukey's P-Value 
#
 
TNF-α 
0 0.62  
35 0.26  
38 0.73  
39 0.89  
49 0.35  
Terminal 0.19  
IFN-α 
0 0.74  
35 0.91  
38 0.26  
39 0.48  
49 0.87  
Terminal 0.19  
IFN-β 
0 0.67  
35 0.41  
38 0.74  
39 0.56  
49 0.35  
Terminal 0.03* 10.22 (1>4) 0.03 
IFN-γ 
0 0.69  
35 1.00  
38 0.77  
39 0.10  
49 0.51  
Terminal 0.33  
TGFB-β1 
0 0.64  
35 0.94  
38 0.57  
39 0.00* 
1.86 (1>4) 0.00 
1.69 (2>3) 0.01 
2.57 (2>4) 0.00 
1.52 (3>4) 0.02 
49 0.01* 
0.39(1<2) 0.04 
1.78 (2>3) 0.02 
Terminal 0.12  
 
Table 18.  (Continued).  
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine 
Study 
Day 
Group Effect 
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
Tukey's P-Value 
#
 
TGFB-β2 
0 0.53  
35 0.99  
38 0.65  
39 0.10  
49 0.46  
Terminal 0.06  
 
Table 18.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
Cytokine 
Days Post Challenge 
0 35 38 39 49 
IL-1β + + + + - 
IL-2 - - - - - 
IL-4 - - - - - 
IL-6 - - + - - 
IL-8 - - - - - 
IL-12p40 - - - - - 
TNF-α - - - - - 
IFN-α - - - - - 
IFN-β - - - - - 
IFN-γ - - - - - 
TGFB-β1 - - - + + 
TGFB-β2 - - - - - 
 
Table 19.  Summary of Significance of Differences in Cytokine Gene Expression 
Between Groups in Whole Blood from Ferrets Challenged with H5N1 virus 
+ = Significant differences between groups (P-value <0.05) 
- = No significant differences between groups (P-value ≥0.05) 
Significance was determined by calculating P-values using ΔCT.  All treatments were on 
Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 was treated with Vaccine 
1, Group 2 was treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 
was treated with a saline control.  Challenge with H5N1 virus was on Day 35.  Data from 
terminal animals are not tabulated since significant differences cannot be determined. 
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Figure 1.   Fold Change in IL-1β mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 2.  Fold Change in IL-2 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 3.  Fold Change in IL-4 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 4.  Fold Change in IL-6 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 5.  Fold Change in IL-8 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 6.   Fold Change in IL-12p40 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 7.  Fold Change in TNF-α mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 8.  Fold Change in IFN-α mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 9.  Fold Change in IFN-β mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 10.  Fold Change in IFN-γ mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 11.  Fold Change in TGFB-β1 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 12.  Fold Change in TGFB-β2 mRNA Levels in Whole Blood from Ferrets 
Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  
Baseline is Day 0 (35 days before challenge).  All treatments were on Day 0 and Day 21 
(35 and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was 
treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated 
with a saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.94 (0.03, 31.76) 
14 49 1 0.10 ( -- ) 
Vaccine 2 2 
4 39 3 0.33 (0.06, 1.91) 
14 49 3 0.04 (0.01, 0.17) 
Vaccine 3 3 
4 39 3 0.11 (0.00, 2.35) 
14 49 8 0.05 (0.02, 0.09) 
Saline 
Control 
4 
4 39 2 1.56 (0.03, 91.17) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.92 (0.155, 5.42) 
14 49 1 0.27 ( -- ) 
Vaccine 2 2 
4 39 3 0.60 (0.18, 2.07) 
14 49 3 0.22 (0.10, 0.52) 
Vaccine 3 3 
4 39 3 0.64 (0.39, 1.04) 
14 49 8 0.50 (0.34, 0.74) 
Saline 
Control 
4 
4 39 2 0.50 (0.00, 100.11) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.63 (0.27, 1.48) 
14 49 1 0.14 ( -- ) 
Vaccine 2 2 
4 39 3 0.44 (0.04, 4.61) 
14 49 3 0.12 (0.03, 0.49) 
Vaccine 3 3 
4 39 3 0.26 (0.02, 2.96) 
14 49 8 0.14 (0.06, 0.33) 
Saline 
Control 
4 
4 39 2 0.42 (0.00, 899.69) 
14 49 NA NA 
 
Table 20.  Fold-change in IL-1β mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available.  
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.01 (0.00, 0.09) 
14 49 1 0.01 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.02) 
14 49 3 0.00 (0.00, 0.02) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 3.44) 
14 49 8 0.00 (0.00, 0.01) 
Saline 
Control 
4 
4 39 2 0.00 (0.00, 27.62) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.02 (0.00, 0.10) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.01 (0.00, 0.05) 
14 49 3 0.01 (0.00, 0.02) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 0.02) 
14 49 8 0.01 (0.01, 0.03) 
Saline 
Control 
4 
4 39 2 0.02 (0.00, 7.73) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.01 (0.01, 0.09) 
14 49 1 0.01 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.03) 
14 49 3 0.01 (0.00, 0.04) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 0.04) 
14 49 8 0.01 (0.03, 0.03) 
Saline 
Control 
4 
4 39 2 0.00 (0.00, 0.04) 
14 49 NA NA 
 
Table 21.  Fold-change in IL-2 mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.00 (0.00, 0.04) 
14 49 1 0.00 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.02) 
14 49 3 0.00 (0.00, 0.02) 
Vaccine 3 3 
4 39 3 0.00 (0.00, 0.07) 
14 49 8 0.00 (0.00, 0.00) 
Saline 
Control 
4 
4 39 2 0.00 (0.00, 21.87) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.00 (0.00, 0.00) 
14 49 1 0.00 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.00) 
14 49 3 0.00 (0.00, 0.00) 
Vaccine 3 3 
4 39 3 0.00 (0.00, 0.00) 
14 49 8 0.00 (0.00, 0.00) 
Saline 
Control 
4 
4 39 2 0.00 (0.00, 0.00) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.00 (0.00, 0.04) 
14 49 1 0.00 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.07) 
14 49 3 0.00 (0.00, 0.00) 
Vaccine 3 3 
4 39 3 0.00 (0.00, 10.84) 
14 49 8 0.00 (0.00, 0.00) 
Saline 
Control 
4 
4 39 2 0.00 (0.00, 0.00) 
14 49 NA NA 
 
Table 22.  Fold-change in IL-4 mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.21 (0.00, 9.54) 
14 49 1 0.05 ( -- ) 
Vaccine 2 2 
4 39 3 0.06 (0.01, 0.32) 
14 49 3 0.05 (0.01, 0.18) 
Vaccine 3 3 
4 39 3 0.07 (0.01, 0.78) 
14 49 8 0.04 (0.02, 0.07) 
Saline 
Control 
4 
4 39 2 0.45 (0.00, 42107.03) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.07 (0.00, 5.93) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.02 (0.01, 0.07) 
14 49 3 0.02 (0.01, 0.04) 
Vaccine 3 3 
4 39 3 0.03 (0.01, 0.14) 
14 49 8 0.03 (0.01, 0.07) 
Saline 
Control 
4 
4 39 2 0.16 (0.00, 150.92) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.63 (0.21, 1.84) 
14 49 1 0.04 ( -- ) 
Vaccine 2 2 
4 39 3 0.54 (0.06, 5.31) 
14 49 3 0.04 (0.00, 0.32) 
Vaccine 3 3 
4 39 3 0.07 (0.01, 0.51) 
14 49 8 0.05 (0.03, 0.09) 
Saline 
Control 
4 
4 39 2 0.15 (0.00, 1346592.43) 
14 49 NA NA 
 
Table 23.  Fold-change in IL-6 mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.25 (0.01, 6.21) 
14 49 1 0.05 ( -- ) 
Vaccine 2 2 
4 39 3 0.06 (0.01, 0.66) 
14 49 3 0.04 (0.01, 0.19) 
Vaccine 3 3 
4 39 3 0.04 (0.00, 0.36) 
14 49 8 0.02 (0.01, 0.04) 
Saline 
Control 
4 
4 39 2 1.51 (0.00, 58384.75) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 1.18 (0.05, 27.99) 
14 49 1 0.10 ( -- ) 
Vaccine 2 2 
4 39 3 0.57 (0.32, 1.01) 
14 49 3 0.15 (0.02, 1.20) 
Vaccine 3 3 
4 39 3 1.05 (0.11, 9.87) 
14 49 8 1.09 (0.25, 4.84) 
Saline 
Control 
4 
4 39 2 1.63 (0.05, 54.19) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.79 (0.14, 4.30) 
14 49 1 0.08 ( -- ) 
Vaccine 2 2 
4 39 3 1.16 (0.32, 3.91) 
14 49 3 0.08 (0.00, 1.50) 
Vaccine 3 3 
4 39 3 0.13 (0.01, 2.21) 
14 49 8 0.04 (0.01, 0.13) 
Saline 
Control 
4 
4 39 2 0.38 (0.00, 12999.78) 
14 49 NA NA 
 
Table 24.   Fold-change in IL-8 mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.30 (0.03, 2.92) 
14 49 1 0.04 ( -- ) 
Vaccine 2 2 
4 39 3 0.19 (0.01, 2.66) 
14 49 3 0.03 (0.01, 0.14) 
Vaccine 3 3 
4 39 3 0.06 (0.00, 1.04) 
14 49 8 0.03 (0.01, 0.06) 
Saline 
Control 
4 
4 39 2 0.34 (0.00, 344.85) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 3.27 (0.91, 11.83) 
14 49 1 1.13 ( -- ) 
Vaccine 2 2 
4 39 3 3.77 (1.98, 7.18) 
14 49 3 0.51 (0.07, 3.53) 
Vaccine 3 3 
4 39 3 0.70 (0.07, 6.65) 
14 49 8 1.01 (0.62, 1.63) 
Saline 
Control 
4 
4 39 2 1.47 (0.36, 5.96) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.13 (0.02, 0.92) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.12 (0.02, 0.78) 
14 49 3 0.02 (0.00, 0.19) 
Vaccine 3 3 
4 39 3 0.02 (0.00, 0.10) 
14 49 8 0.02 (0.01, 0.05) 
Saline 
Control 
4 
4 39 2 0.06 (0.00, 2.99) 
14 49 NA NA 
 
Table 25.  Fold-change in IL-12p40 mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 20.58 (2.010, 201.89) 
14 49 1 2.18 ( -- ) 
Vaccine 2 2 
4 39 3 8.56 (1.44, 50.98) 
14 49 3 1.47 (0.69, 3.12) 
Vaccine 3 3 
4 39 3 2.56 (0.38, 17.46) 
14 49 8 1.51 (1.11, 2.06) 
Saline 
Control 
4 
4 39 2 37.21 (0.01, 138383.91) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 10.29 (4.15, 25.52) 
14 49 1 0.55 ( -- ) 
Vaccine 2 2 
4 39 3 6.33 (1.64, 24.46) 
14 49 3 1.08 (0.20, 5.76) 
Vaccine 3 3 
4 39 3 1.99 (0.32, 12.38) 
14 49 8 2.78 (1.14, 6.79) 
Saline 
Control 
4 
4 39 2 10.65 (0.63, 179.65) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 4.02 (1.05, 15.35) 
14 49 1 0.99 ( -- ) 
Vaccine 2 2 
4 39 3 3.29 (1.04, 10.38) 
14 49 3 1.51 (0.28, 8.03) 
Vaccine 3 3 
4 39 3 1.11 (0.48, 2.58) 
14 49 8 0.81 (0.55, 1.20) 
Saline 
Control 
4 
4 39 2 1.76 (0.10, 32.63) 
14 49 NA NA 
 
Table 26.  Fold-change in TNF-α mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.02 (0.00, 0.10) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.02 (0.00, 0.06) 
14 49 3 0.02 (0.00, 0.07) 
Vaccine 3 3 
4 39 3 0.03 (0.00, 0.92) 
14 49 8 0.01 (0.01, 0.03) 
Saline 
Control 
4 
4 39 2 0.03 (0.00, 4552.83) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.01 (0.00, 0.12) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.00 (0.00, 0.01) 
14 49 3 0.01 (0.00, 0.03) 
Vaccine 3 3 
4 39 3 0.00 (0.00, 0.01) 
14 49 8 0.01 (0.00, 0.01) 
Saline 
Control 
4 
4 39 2 0.01 (0.00, 0.27) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.04 (0.01, 0.16) 
14 49 1 0.01 ( -- ) 
Vaccine 2 2 
4 39 3 0.03 (0.00, 0.17) 
14 49 3 0.00 (0.00, 0.01) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 0.03) 
14 49 8 0.01 (0.00, 0.03) 
Saline 
Control 
4 
4 39 2 0.04 (0.00, 0.21) 
14 49 NA NA 
 
Table 27.  Fold-change in IFN-α mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.14 (0.06, 0.33) 
14 49 1 0.34 ( -- ) 
Vaccine 2 2 
4 39 3 0.22 (0.03, 1.64) 
14 49 3 0.37 (0.18, 0.75) 
Vaccine 3 3 
4 39 3 0.25 (0.04, 1.65) 
14 49 8 0.29 (0.19, 0.44) 
Saline 
Control 
4 
4 39 2 0.28 (0.00, 577.14) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.03 (0.00, 0.27) 
14 49 1 0.02 ( -- ) 
Vaccine 2 2 
4 39 3 0.01 (0.01, 0.02) 
14 49 3 0.01 (0.00, 0.04) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 0.03) 
14 49 8 0.01 (0.01, 0.02) 
Saline 
Control 
4 
4 39 2 0.04 (0.00, 0.35) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.16 (0.05, 0.53) 
14 49 1 0.01 ( -- ) 
Vaccine 2 2 
4 39 3 0.10 (0.018, 0.51) 
14 49 3 0.01 (0.00, 0.02) 
Vaccine 3 3 
4 39 3 0.01 (0.00, 0.04) 
14 49 8 0.02 (0.01, 0.04) 
Saline 
Control 
4 
4 39 2 0.06 (0.00, 22.84) 
14 49 NA NA 
 
Table 28.  Fold-change in IFN-β mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Sample 
Type 
Treatment Group 
Day Post 
Challenge 
Study 
Day 
N 
Geometric Mean (95% 
Confidence Interval) 
Brain 
Vaccine 1 1 
4 39 3 0.31 (0.02, 5.97) 
14 49 1 0.09 ( -- ) 
Vaccine 2 2 
4 39 3 0.09 (0.02, 0.49) 
14 49 3 0.09 (0.02, 0.32) 
Vaccine 3 3 
4 39 3 0.12 (0.02, 0.82) 
14 49 8 0.07 (0.04, 0.14) 
Saline 
Control 
4 
4 39 2 0.26 (0.00, 227.26) 
14 49 NA NA 
Liver 
Vaccine 1 1 
4 39 3 0.79 (0.06, 10.28) 
14 49 1 0.05 ( -- ) 
Vaccine 2 2 
4 39 3 0.22 (0.05, 0.97) 
14 49 3 0.08 (0.02, 0.28) 
Vaccine 3 3 
4 39 3 0.16 (0.01, 2.87) 
14 49 8 0.27 (0.06, 1.12) 
Saline 
Control 
4 
4 39 2 1.31 (0.15, 11.72) 
14 49 NA NA 
Lung 
Vaccine 1 1 
4 39 3 0.76 (0.01, 69.78) 
14 49 1 0.04 ( -- ) 
Vaccine 2 2 
4 39 3 1.73 (0.52, 5.67) 
14 49 3 0.03 (0.00, 0.32) 
Vaccine 3 3 
4 39 3 0.03 (0.01, 0.09) 
14 49 8 0.03 (0.01, 0.05) 
Saline 
Control 
4 
4 39 2 0.24 (0.00, 11.81) 
14 49 NA NA 
 
Table 29.  Fold-change in IFN-γ mRNA Levels in Brain, Liver, and Lung from 
Ferrets Challenged with H5N1 virus 
-- Confidence interval was not calculated since there was only one observation available. 
NA No data were available. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
IL-1β 
Brain 
39 0.05  
49 <0.00* 
0.10 (1<5) 0.00 
0.04 (2<5) <0.00 
0.045 (3<5) <0.00 
Liver 
39 0.44  
49 0.00* 
0.44 (2<3) 0.05 
0.22 (2<5) 0.00 
Lung 
39 0.30  
49 0.01* 
0.12 (2<5) 0.02 
0.14 (3<5) 0.01 
IL-2 
Brain 
39 0.00* 
0.01 (1<5) 0.01 
0.00 (2<5) 0.00 
0.01 (3<5) 0.01 
0.00 (4<5) 0.01 
49 <0.00* 
0.01 (1<5) 0.00 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
Liver 
39 <0.00* 
0.02 (1<5) <0.00 
0.01 (2<5) <0.00 
0.01 (3<5) <0.00 
0.02 (4<5) <0.00 
49 <0.00* 
0.02 (1<5) 0.00 
0.01 (2<5) <0.00 
0.01 (3<5) <0.00 
Lung 
39 <0.00* 
0.01 (1<5) <0.00 
0.00 (2<5) <0.00 
0.01 (3<5) 0.00 
0.00 (4<5) <0.00 
49 <0.00* 
0.01 (1<5) 0.00 
0.01 (2<5) <0.00 
0.01 (3<5) <0.00 
 
Table 30.  Results of ANOVA Models Fitted to     for Cytokine Gene 
Expression in Brain, Liver, and Lung from Ferrets Challenged with H5N1 virus. 
 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
IL-4 
Brain 
39 <0.00* 
0.00 (1<5) 0.00 
0.00 (2<5) 0.00 
0.00 (3<5) 0.00 
0.00 (4<5) 0.00 
49 <0.00* 
0.00 (1<5) 0.00 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
Liver 
39 <0.00* 
0.00 (1<5) <0.00 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
0.00 (4<5) <0.00 
49 <0.00* 
6.08 (1>3) 0.01 
0.00 (1<5) <0.00 
2.86 (2>3) 0.01 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
Lung 
39 0.00* 
0.00 (1<5) 0.01 
0.00 (2<5) 0.00 
0.00 (4<5) 0.00 
49 <0.00* 
0.00 (1<5) <0.00 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
IL-6 
Brain 
39 0.03* 0.06 (2<5) 0.05 
49 <0.00* 
0.05 (1<5) 0.00 
0.05 (2<5) <0.00 
0.04 (3<5) <0.00 
Liver 
39 0.01* 
0.07 (1<5) 0.05 
0.02 (2<5) 0.01 
0.03 (3<5) 0.01 
49 <0.00* 
0.02 (1<5) 0.00 
0.02 (2<5) <0.00 
0.03 (3<5) <0.00 
Lung 
39 0.02* 0.07 (3<5) 0.0233 
49 <0.00* 
0.04 (1<5) 0.00 
0.04 (2<5) <0.00 
0.05 (3<5) <0.00 
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
IL-8 
Brain 
39 0.01* 
0.04 (2<4) 0.03 
0.06 (2<5) 0.03 
0.03 (3<4) 0.01 
0.04 (3<5) 0.01 
49 <0.00* 
0.05 (1<5) 0.01 
0.04 (2<5) 0.00 
0.02 (3<5) <0.00 
Liver 
39 0.64  
49 0.18  
Lung 
39 0.04* 8.35 (2>3) 0.05 
49 0.01* 0.04 (3<5) 0.01 
IL-12p40 
Brain 
39 0.04* 0.06 (3<5) 0.02 
49 <0.00* 
0.04 (1<5) 0.00 
0.03 (2<5) <0.00 
0.03 (3<5) <0.00 
Liver 
39 0.01* 
4.70 (1>3) 0.03 
5.41 (2>3) 0.02 
49 0.34  
Lung 
39 0.00* 
6.27 (1>3) 0.03 
0.13 (1<5) 0.02 
5.78 (2>3) 0.04 
0.12 (2<5) 0.01 
0.02 (3<5) 0.00 
0.06 (4<5) 0.00 
49 <0.00* 
0.02 (1<5) 0.00 
0.02 (2<5) <0.00 
0.02 (3<5) <0.00 
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
TNF-α 
Brain 
39 0.00* 
8.04 (1>3) 0.04 
20.58 (1>5) 0.00 
8.56 (2>5) 0.03 
0.07 (3<4) 0.02 
37.21 (4>5) 0.00 
49 0.06  
Liver 
39 0.00* 
5.18 (1>3) 0.01 
10.29 (1>5) 0.00 
6.33 (2>5) 0.01 
0.17 (3<4) 0.02 
10.65 (4>5) 0.00 
49 0.17  
Lung 
39 0.01* 
3.62 (1>3) 0.02 
4.02 (1>5) 0.01 
2.96 (2>3) 0.04 
3.29 (2>5) 0.03 
49 0.30  
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
IFN-α 
Brain 
39 0.00* 
0.02 (1<5) 0.00 
0.02 (2<5) 0.00 
0.03 (3<5) 0.01 
0.03 (4<5) 0.01 
49 <0.00* 
0.02 (1<5) <0.00 
0.02 (2<5) <0.00 
0.01 (3<5) <0.00 
Liver 
39 <0.00* 
0.01 (1<5) <0.00 
0.00 (2<5) <0.00 
0.00 (3<5) <0.00 
0.01 (4<5) 0.00 
49 <0.00* 
0.02 (1<5) 0.00 
0.01 (2<5) <0.00 
0.01 (3<5) <0.00 
Lung 
39 <0.00* 
5.38 (1>3) 0.03 
0.04 (1<5) 0.00 
0.03 (2<5) 0.00 
0.01 (3<5) <0.00 
0.01 (4<5) <0.00 
49 <0.00* 
0.01 (1<5) 0.00 
0.00 (2<5) <0.00 
0.01 (3<5) <0.00 
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Table 30.  (Continued). 
 
Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
IFN-β 
Brain 
39 0.03* 0.14 (1<5) 0.02 
49 0.00* 
0.34 (1<5) 0.01 
0.37 (2<5) 0.00 
0.29 (3<5) <0.00 
Liver 
39 <0.00* 
0.03 (1<5) 0.00 
0.01 (2<5) <0.00 
0.15 (3<4) 0.03 
0.01 (3<5) <0.00 
0.04 (4<5) 0.00 
49 <0.00* 
0.02 (1<5) 0.00 
0.01 (2<5) <0.00 
0.01 (3<5) <0.00 
Lung 
 
39 <0.00* 
14.78 (1>3) 0.00 
0.16 (1<5) 0.01 
9.04 (2>3) 0.00 
0.10 (2<5) 0.00 
0.19 (3<4) 0.04 
0.01 (3<5) <0.00 
0.06 (4<5) 0.00 
49 <0.00* 
0.01 (1<5) 0.00 
0.01 (2<5) <0.00 
0.02 (3<5) <0.00 
IFN-γ 
 
Brain 
 
39 0.03* 
0.0903 (2<5) 0.0265 
0.1158 (3<5) 0.0470 
49 <0.00* 
0.09 (1<5) 0.00 
0.09 (2<5) <0.00 
0.07 (3<5) <0.00 
Liver 
39 0.04*  
49 0.13  
Lung 
 
39 0.00* 
29.97 (1>3) 0.01 
68.01 (2>3) 0.00 
0.03 (3<5) 0.01 
49 <0.00* 
0.04 (1<5) 0.00 
0.03 (2<5) <0.00 
0.03 (3<5) <0.00 
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine Sample Type 
Study 
Day 
Group 
Effect  
P-value 
Estimated Ratio of 2
-ΔCt
 
(Relationship) 
 Tukey's P-Value 
#
 
TGFB-β1 
Brain 
39 0.54  
49 0.41  
Liver 
39 0.02* 
2.72 (1>3) 0.03 
0.31 (3<4) 0.03 
49 0.28  
Lung 
39 0.71  
49 0.41  
TGFB-β2 
Brain 
39 0.09  
49 0.15  
Liver 
39 0.35  
49 0.17  
Lung 
39 0.05* 0.28 (1<3) 0.05 
49 0.60  
 
Table 30.  (Continued). 
#  Cells contain all significant pairwise group comparisons at the 0.05 level.  The format within 
each cell is:  (1) the ratio of geometric means, (2) the relationship between corresponding 
group geometric means, and (3) the Tukey-adjusted P-value. 
*  The overall group effect is significant at the 0.05 level. 
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Cytokine 
Days Post Challenge 
4 14 
IL-1β - + 
IL-2 + + 
IL-4 + + 
IL-6 + + 
IL-8 + + 
IL-12p40 + + 
TNF-α + - 
IFN-α + + 
IFN-β + + 
IFN-γ + + 
TGFB-β1 - - 
TGFB-β2 - - 
 
Table 31. Summary of Significance of Differences in Cytokine Expression Between 
Groups in Brain from Ferrets Challenged with H5N1 virus 
+ = Significant differences between groups (P-value <0.05) 
- = No significant differences between groups (P-value ≥0.05) 
Significance was determined by calculating P-values using ΔCT.  All treatments were on 
Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 was treated with Vaccine 
1, Group 2 was treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 
was treated with a saline control.  Challenge with H5N1 virus was on Day 35.  Data from 
terminal animals are not tabulated since significant differences cannot be determined. 
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Cytokine 
Days Post Challenge 
4 14 
IL-1β - + 
IL-2 + + 
IL-4 + + 
IL-6 + + 
IL-8 - - 
IL-12p40 + - 
TNF-α + - 
IFN-α + + 
IFN-β + + 
IFN-γ + - 
TGFB-β1 + - 
TGFB-β2 - - 
 
Table 32. Summary of Significance of Differences in Cytokine Gene Expression 
Between Groups in Liver from Ferrets Challenged with H5N1 virus 
+ = Significant differences between groups (P-value <0.05) 
- = No significant differences between groups (P-value ≥0.05) 
Significance was determined by calculating P-values using ΔCT.  All treatments were on 
Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 was treated with Vaccine 
1, Group 2 was treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 
was treated with a saline control.  Ferrets were challenged with H5N1 virus was on Day 
35.  Data from terminal animals are not tabulated since significant differences cannot be 
determined. 
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Cytokine 
Days Post Challenge 
4 14 
IL-1β - + 
IL-2 + + 
IL-4 + + 
IL-6 + + 
IL-8 + + 
IL-12p40 + + 
TNF-α + - 
IFN-α + + 
IFN-β + + 
IFN-γ + + 
TGFB-β1 - - 
TGFB-β2 + - 
 
Table 33.  Summary of Significance of Differences in Cytokine Gene Expression 
Between Groups in Lung from Ferrets Challenged with H5N1 virus 
+ = Significant differences between groups (P-value <0.05) 
- = No significant differences between groups (P-value ≥0.05) 
Significance was determined by calculating P-values using ΔCT.  All treatments were on 
Day 0 and Day 21 (35 and 14 days before challenge).  Group 1 was treated with Vaccine 
1, Group 2 was treated with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 
was treated with a saline control.  Challenge with H5N1 virus was on Day 35.  Data from 
terminal animals are not tabulated since significant differences cannot be determined. 
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Figure 13.  Fold Change in IL-1β mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 14.  Fold Change in IL-2 mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 15.  Fold Change in IL-4 mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 16.  Fold Change in IL-6 mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 17.  Fold Change in IL-8 mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 18.  Fold Change in IL-12p40 mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
 
 
86 
 
Figure 19.  Fold Change in TNF-α mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 20.  Fold Change in IFN-α mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 21.  Fold Change in IFN-β mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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Figure 22.  Fold Change in IFN-γ mRNA Levels in Lung, Liver, and Brain from 
Ferrets Challenged with H5N1 Virus. 
Fold changes are expressed as 2
-ΔΔCT
, using GAPDH expression as the calibrator.  The 
baseline is expression from 3 naïve ferrets.  All treatments were on Day 0 and Day 21 (35 
and 14 days before challenge).  Group 1 was treated with Vaccine 1, Group 2 was treated 
with Vaccine 2, Group 3 was treated with Vaccine 3, and Group 4 was treated with a 
saline control.  Ferrets were challenged with H5N1 virus on Day 35. 
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